142 related articles for article (PubMed ID: 8639311)
1. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for non-Hodgkin's lymphomas: a Swedish national prospective study. Swedish Lymphoma Study Group.
Enblad G; Hagberg H; Glimelius B
Acta Oncol; 1996; 35(2):165-70. PubMed ID: 8639311
[TBL] [Abstract][Full Text] [Related]
2. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease and non-Hodgkin's lymphoma. The Swedish Lymphoma Study Group.
Enblad G; Glimelius B; Hagberg H; Lindemalm C
Acta Oncol; 1990; 29(3):297-301. PubMed ID: 2363941
[TBL] [Abstract][Full Text] [Related]
3. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease: a prospective study.
Enblad G; Hagberg H; Gustavsson A; Glimelius B
Eur J Haematol; 1998 Mar; 60(3):166-71. PubMed ID: 9548415
[TBL] [Abstract][Full Text] [Related]
4. Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's lymphoma.
Hopfinger G; Heinz R; Koller E; Schneider B; Pittermann E
Eur J Haematol; 1995 Oct; 55(4):223-7. PubMed ID: 7589338
[TBL] [Abstract][Full Text] [Related]
5. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
[TBL] [Abstract][Full Text] [Related]
10. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
11. MIME combination chemotherapy in recurrent or refractory lymphoproliferative malignancies. A phase II study.
Mirza MR; Brincker H
Acta Oncol; 1991; 30(1):17-21. PubMed ID: 2009179
[TBL] [Abstract][Full Text] [Related]
12. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease.
Cabanillas F; Velasquez WS; McLaughlin P; Jagannath S; Hagemeister FB; Redman JR; Swan F; Rodriguez MA
Semin Hematol; 1988 Apr; 25(2 Suppl 2):47-50. PubMed ID: 3041599
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
[TBL] [Abstract][Full Text] [Related]
14. European experience with ifosfamide in lymphomas.
von Kalle AK; Schaadt M; Diehl V
Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
[TBL] [Abstract][Full Text] [Related]
15. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
Martelli M; Vignetti M; Zinzani PL; Gherlinzoni F; Meloni G; Fiacchini M; De Sanctis V; Papa G; Martelli MF; Calabresi F; Tura S; Mandelli F
J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.
Zinzani PL; Barbieri E; Visani G; Gherlinzoni F; Perini F; Neri S; Bendandi M; Ammendolia I; Salvucci M; Babini L
Haematologica; 1994; 79(6):508-12. PubMed ID: 7534744
[TBL] [Abstract][Full Text] [Related]
17. Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas.
Nowrousian MR; Anders CH; Niederle N; Nagel-Hiemke M; Moritz T; Seeber S; Schmidt CG
Ann Oncol; 1991 Jan; 2 Suppl 1():25-30. PubMed ID: 1710486
[TBL] [Abstract][Full Text] [Related]
18. [IEMAD (modified MIME) therapy for refractory or relapsed non-Hodgkin's lymphoma].
Li HH; Wu XX; Wang QS; Zhao Y; Bo J; Wang SH; DA WM; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr; 14(2):298-300. PubMed ID: 16638201
[TBL] [Abstract][Full Text] [Related]
19. Salvage therapy with ProMACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first-line CHOP.
Verdonck LF; Dekker AW; de Gast GC; van Kempen ML; Lokhorst HM; Nieuwenhuis HK
J Clin Oncol; 1992 Dec; 10(12):1949-54. PubMed ID: 1453209
[TBL] [Abstract][Full Text] [Related]
20. VIM3-ARA C: an effective salvage regimen in refractory or recurrent aggressive non Hodgkin's lymphoma. A report on 18 cases.
Dupriez B; Morel P; Fenaux P; Colcher-Plantier I; Facon T; Bauters F
Hematol Oncol; 1991; 9(4-5):259-66. PubMed ID: 1743628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
